医学
免疫抑制
美罗华
肾移植
内科学
免疫学
球蛋白
临床试验
移植
抗体
作者
James F. Markmann,Bryna E. Burrell,Jonathan S. Bromberg,Choli Hartono,Dixon B. Kaufman,Andrew M. Possselt,Ali Naji,Nancy D. Bridges,Cynthia Breeden,Sai Kanaparthi,Jorge Pardo,Heather Kopetskie,Kristen Mason,Noha Lim,Sindhu Chandran
标识
DOI:10.1016/j.ajt.2024.03.007
摘要
Durable tolerance in kidney transplant recipients remains an important but elusive goal. We hypothesized that adding B cell depletion to T cell depletion would generate an immune milieu postreconstitution dominated by immature transitional B cells, favoring tolerance. The Immune Tolerance Network ITN039ST Research Study of ATG and Rituximab in Renal Transplantation was a prospective multicenter pilot study of live donor kidney transplant recipients who received induction with rabbit antithymocyte globulin and rituximab and initiated immunosuppression (IS) withdrawal (ISW) at 26 weeks. The primary endpoint was freedom from rejection at 52 weeks post-ISW. Six of the 10 subjects successfully completed ISW. Of these 6 subjects, 4 restarted immunosuppressive medications due to acute rejection or recurrent disease, 1 remains IS-free for over 9 years, and 1 was lost to follow-up after being IS-free for 42 weeks. There were no cases of patient or graft loss. CD19
科研通智能强力驱动
Strongly Powered by AbleSci AI